Allogenic faecal microbiota transplantation for antibiotic-associated diarrhoea in critically ill patients (FEBATRICE)–Study protocol for a multi-centre randomised controlled trial (phase II)
PLOS ONE · 27.12.2024 · 19 (12) · e0310180
DOI: 10.1371/journal.pone.0310180 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, online erschienen am 27.12.2024. Verfasst von Ivana Cibulkova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Kralovske Vinohrady University Hospital, Prague, Czech Republic. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Critical Illness, Diarrhea, Fecal Microbiota Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Donatio Intensivistam Endowment Fund.
Abstract (Originalsprache)
Background
Exposure of critically ill patients to antibiotics lead to intestinal dysbiosis, which often manifests as antibiotic-associated diarrhoea. Faecal microbiota transplantation restores gut microbiota and may lead to faster resolution of diarrhoea.
Methods
Into this prospective, multi-centre, randomized controlled trial we will enrol 36 critically ill patients with antibiotic-associated diarrhoea. We will exclude patients with ongoing sepsis, need of systemic antibiotics, or those after recent bowel surgery or any other reason that prevents the FMT. Randomisation will be in 1:1 ratio. Patients in the control group will receive standard treatment based on oral diosmectite. In the intervention group, patients will receive, in addition to the standard of care, faecal microbiota transplantation via rectal tube, in the form of a preparation mixed from 7 thawed aliquots (50 mL) made from fresh stool of 7 healthy unrelated donors and quarantined deep frozen for 3 to 12 months. Primary outcome is treatment failure defined as intervention not delivered or diarrhoea persisting at day 7 after randomisation. Secondary outcomes include safety measures such as systemic inflammatory response, adverse events, and also diarrhoea recurrence within 28 days. Exploratory outcomes focus on gut barrier function and composition of intestinal microbiota.
Discussion
Faecal microbiota transplantation has been effective for dysbiosis in non-critically ill patients with recurrent C . difficile infections and it is plausible to hypothesize that it will be equally effective for symptoms of dysbiosis in the critically ill patients. In addition, animal experiments and observational data suggest other benefits such as reduced colonization with multi-drug resistant bacteria and improved gut barrier and immune function. The frozen faeces from unrelated donors are immediately available when needed, unlike those from the relatives, who require lengthy investigation. Using multiple donors maximises graft microbiota diversity. Nonetheless, in vulnerable critically ill patients, Faecal microbiota transplantation might lead to bacterial translocation and unforeseen complications. From growing number of case series it is clear that its off label use in the critically ill patients is increasing and that there is a burning need to objectively assess its efficacy and safety, which this trial aims. Trial registration www.clinicaltrials.gov ( NCT05430269 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Kralovske Vinohrady University Hospital, Prague, Czech Republic.
- The Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- Department of Anaesthesia and Intensive Care Medicine, Kralovske Vinohrady University Hospital, Prague, Czech Republic.
- Department of Microbiology, Kralovske Vinohrady University Hospital, Prague, Czech Republic.
- Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 3rd Department of Internal Medicine-Metabolism and Gerontology, Charles University Teaching Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
ORCID-Profile: Monika Cahova, Frantisek Duska
Förderung
- Donatio Intensivistam Endowment Fund
Zitieren
APA
Cibulkova, I., Rehorova, V., Soukupova, H., Waldauf, P., Cahova, M., Manak, J., Matejovic, M., & Duska, F. (2024). Allogenic faecal microbiota transplantation for antibiotic-associated diarrhoea in critically ill patients (FEBATRICE)–Study protocol for a multi-centre randomised controlled trial (phase II). PLOS ONE, 19(12), e0310180. https://doi.org/10.1371/journal.pone.0310180
Vancouver
Cibulkova I, Rehorova V, Soukupova H, Waldauf P, Cahova M, Manak J, et al. Allogenic faecal microbiota transplantation for antibiotic-associated diarrhoea in critically ill patients (FEBATRICE)–Study protocol for a multi-centre randomised controlled trial (phase II). PLOS ONE. 2024;19(12):e0310180. doi:10.1371/journal.pone.0310180
BibTeX
@article{Cibulkova2024,
author = {Cibulkova, Ivana and Rehorova, Veronika and Soukupova, Hana and Waldauf, Petr and Cahova, Monika and Manak, Jan and Matejovic, Martin and Duska, Frantisek},
title = {Allogenic faecal microbiota transplantation for antibiotic-associated diarrhoea in critically ill patients (FEBATRICE)–Study protocol for a multi-centre randomised controlled trial (phase II)},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {12},
pages = {e0310180},
doi = {10.1371/journal.pone.0310180}
}
EUVIMED